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Objective: Recent research has assessed the impact
of tobacco laws on cardiovascular and respiratory
morbidity. In this study, we also examined whether the
association between the implementation of the 2005
Spanish smoking ban and hospital admissions for
cardiovascular and respiratory diseases varies
according to the adjustment for potential confounders.
Design: Ecological time series analysis.
Setting: Residents of Madrid and Barcelona cities
(Spain).
Outcome: Data on daily emergency room admissions
for acute myocardial infarction, cerebrovascular
disease, chronic obstructive pulmonary disease
(COPD), and asthma derived from the 2003–2006
Spanish hospital admissions registry.
Methods: Changes in admission rates between 2006
and the 2003–2005 period were estimated using
additive Poisson models allowing for overdispersion
adjusted for secular trend in admission, seasonality,
day of the week, temperature, number of flu and acute
respiratory infection cases, pollution levels, tobacco
consumption prevalence and, for asthma cases, pollen
count.
Results: In Madrid, fully adjusted models failed to
detect significant changes in hospital admission rates
for any disease during the study period. In Barcelona,
however, hospital admissions decreased by 10.2%
(95% CI 3.8% to 16.1%) for cerebrovascular diseases
and by 16.0% (95% CI 7.0% to 24.1%) for COPD.
Substantial changes in effect estimates were observed
on adjustment for linear or quadratic trend. Effect
estimates for asthma-related admissions varied
substantially when adjusting for pollen count in
Madrid, and for seasonality and tobacco consumption
in Barcelona.
Conclusions: Our results confirm that the potential
impact of a smoking ban must be adjusted for the
underlying secular trend. In asthma-related admissions,
pollen count, seasonality and tobacco consumption
must be specified in the model. The substantial
variability in effects detected between the two cities of
Madrid and Barcelona lends strong support for a
nationwide study to assess the overall effect of a
smoking ban in Spain and identify the causes of the
observed heterogeneity.
INTRODUCTION
Secondhand smoke (SHS) exposure
accounts for 0.7% of worldwide disease
burden or disability-adjusted life years by
increasing the risk of cardiovascular and
chronic obstructive respiratory diseases,
among other health problems.1 2
Existing evidence consistently shows that
even low levels of SHS exposure are quick to
adversely affect heart function, blood and
vascular systems, increasing the risk for
ischaemic heart disease by about 30%.3–5
Recent evidence now includes cerebrovascu-
lar diseases as part of the SHS disease
burden as well.6 Even when support for a
causal relationship between SHS and respira-
tory disease is inconclusive,1 a reduction in
risk for such pathologies has been observed
following the implementation of comprehen-
sive smoke-free laws for reducing SHS
exposure.7
Strengths and limitations of this study
▪ The analysis of the effect of smoking bans on
health must be adjusted for the underlying
secular trend and controlling for potential
confounders.
▪ The variability in estimates observed across the
two cities in the same country strongly suggests
the need to study a larger number of regions to
globally assess the impact of smoking laws on
health outcomes.
▪ The smoking ban was implemented in all regions
of Spain simultaneously; thus, we were unable to
compare our results against a control population.
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A review8 on the effect of smoke-free legislation con-
cluded that these laws are effective in reducing SHS
exposure; however, evidence on their impact on active
tobacco consumption is limited. In January 2006, Spain
implemented law 28/2005 on healthcare measures
regarding tobacco consumption,9 which banned smoking
at the workplace and imposed a partial ban on restau-
rants, bars and any establishment serving food and/or
beverages. This law achieved a substantial reduction in
SHS exposure in the workplace but with little impact on
exposure at restaurants, bars and similar venues.10–12
Many studies have assessed the impact of regulations
to prevent SHS exposure, including the impact on hos-
pital admissions for cardiovascular and respiratory dis-
eases.7 13–27 Although most are based on time-series
analysis, many fail to account for potentially confound-
ing variables and estimates are highly sensitive to adjust-
ment for the non-linearity in secular trend.28 29
Our main aim is to assess the impact of smoke-free
legislation on cardiovascular and respiratory morbidity
in two large Spanish cities while ascertaining the effect
of potential confounders. Results will inform the analyt-
ical plan of data provided by other regions in Spain.
METHODS
Study population
Our study population consists of all the residents of
Madrid and Barcelona with an average population size
during the study period of 3 124 090 and 1 591 529 inha-
bitants, respectively. Data were compiled from hospital
admission records from the Basic Minimum Set of Data
(BMSD) from January 2003 to December 2006. This
data set records admissions to hospitals included in the
National Healthcare System, both public hospitals and
private ones within the consortium. We analysed the
number of daily emergency admissions for acute myocar-
dial infarction as the primary diagnosis, except for
ensuing episodes (International Classification of
Diseases, ICD 9, 410.x.0 and 410.x.1) in those 18 years
of age and older; cerebrovascular disease (ICD 9, 430–
438) in those 18 years of age and older; chronic
obstructive pulmonary disease (COPD) (ICD 9, 490–
492; 494–496) in those at least 40 years of age; and
asthma (ICD 9, 493) regardless of age.
To guarantee the confidentiality of the patients, the
information of clinical records was anonymised and
de-identified prior to analysis.
Analysis
Changes in hospital admission rates during the first year
of the smoking ban were estimated using an indicator
variable for the year 2006 in additive Poisson with over-
dispersion. The long-term secular trend was adjusted by
including a homogeneous linear term all along the day
series. If significant deviations from linearity were
detected during the time period preceding the smoking
ban, a quadratic term was also included in the series.
Seasonality was modelled using harmonic terms and
indicator variables for the days of the week. We adjusted
for the following potential confounders (data source):
maximum daily temperature (National Institute of
Meteorology), including up to seven time lags; number
of flu cases (Sentinel Physician Network of the Influenza
Surveillance System in Spain): the weekly datum was
interpolated as a daily value, including up to 10 time
lags; daily emergency hospital admissions (BMSD) for
acute respiratory infections, with up to 10 time lags. Air
pollution was assessed on the basis of daily pollutant
levels using 24 h averages (µg/m3) of SO2, particulate
matter (PM10) and NO2 and the maximum value for the
8 h average for O3. We examined five time lags for SO2,
four lags for PM10 and NO2, and nine lags for O3.
Pollen data were included when examining admissions
due to asthma. The variable pollen was estimated on the
basis of the daily count (grains/m3) of Poaceae,
Plantago, Olea and Urticaceae and up to four time lags
for pollen were included. We also adjusted for the per-
centage of the population over 16 years of age consum-
ing tobacco with any frequency. Data came from the
2003 and 2006 National Health Surveys. Tobacco con-
sumption data from 2003 were applied to years 2003 and
2004 and tobacco data from 2006 were applied to years
2005 and 2006, adjusting for population size at the time.
Temperature, air pollution and pollen count variables
were included in the model using smoothing splines
with up to four degrees of freedom.
We ran sequential models to examine changes in coef-
ficients according to levels of adjustment (each model
builds on the previous one): (1) basic model with no
adjustment; (2) adjusting for long-term trend; (3) adjust-
ing for seasonality and controlling for the day of the
week, flu and acute respiratory infections; (4) controlling
for air pollution and (5) finally, the complete model also
controls for tobacco consumption. For asthma cases, we
also ran a model to assess the potential confounding
effect of pollen count on the association between the
smoking ban and hospital admissions for asthma.
RESULTS
Table 1 shows crude hospital admission rates (per thou-
sand inhabitants) for each study year. Table 2 shows
these rate distributions for each of the daily series, as
well as the distribution of the study covariates. Barcelona
reported greater rates of cardiovascular diseases and
COPD and Madrid reported more cases of asthma.
During the period preceding the smoking ban (2003–
2005) series trends are linear, for the most part, except
for COPD for which we observe a statistically significant
quadratic trend in both cities (table 1 and figure 1).
Figure 1 shows seasonal patterns with highs during
winter months and lows during the summer; these pat-
terns are especially pronounced for COPD and, to a
lesser extent, for myocardial infarction. Asthma in
Madrid experiences an increase during the months of
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May and June and again in September, whereas season-
ality is not as easy to spot in Barcelona. Cerebrovascular
disease does not reveal a seasonal pattern.
Table 3 shows the effects of the ban on admissions for
cardiovascular diseases according to models with sequen-
tial adjustment for potential confounders. Results are
expressed as a change in percentage of admissions
reported in 2006 compared to those reported during the
2003–2005 period. On the basis of the fully adjusted
model (model E), admissions in Madrid for acute myo-
cardial infarction experienced a non-significant increase
of 6.6% (95% CI −1.5% to 15.5%) and, in Barcelona, a
non-significant decrease of −6.3% (95% CI −14.7% to
2.9%). The greatest change in estimate in both cities was
observed when we controlled for trend. Sequential adjust-
ment for seasonality and related variables, pollution and
tobacco consumption does not have a substantial effect
on the estimates. Regarding cerebrovascular disease,
whereas the fully adjusted model (model E) for Madrid
reveals no association, results for Barcelona point to a
statistically significant decrease in admissions of over 10%
associated with the implementation of the smoking
ban −3.8%: (−10.2% (95% CI −16.1% to −3.8%)). As
described above, the greatest change in estimates is
observed in both cities when the association is adjusted
for trend.
Table 4 shows the effects of the ban on admissions for
respiratory diseases according to models with sequential
adjustment for potential confounders. Fully adjusted esti-
mates, including for linear trend (model E), indicate a
statistically significant reduction of 16% in hospital
admissions for COPD in Madrid (95% CI −21.6% to
Table 1 Hospital admissions for cardiovascular and respiratory diseases















Myocardial infarction 2528 0.96 2483 0.94 2431 0.91 0.093 0.981 2431 0.92
Cerebrovascular disease 4045 1.50 4130 1.56 4368 1.64 0.002 0.297 4297 1.62
COPD 4319 2.68 4203 2.86 4478 3.38 0.665 0.014 3515 2.97
Asthma 1054 0.34 1114 0.36 1145 0.36 0.111 0.760 1399 0.45
Barcelona
Myocardial infarction 1843 1.36 1938 1.42 1847 1.35 0.756 0.074 1726 1.26
Cerebrovascular disease 3075 2.27 3305 2.43 3395 2.47 0.001 0.235 3208 2.34
COPD 4545 5.47 4207 5.04 4371 5.19 0.012 0.003 2817 3.33
Asthma 298 0.19 330 0.21 302 0.19 0.989 0.153 235 0.15
Madrid and Barcelona (Spain), 2003–2006 period.
COPD, chronic obstructive pulmonary disease.
Table 2 Distribution of study variables (daily values)
Madrid Barcelona
Mean (SD) P5* P25 P50 P75 P95 Mean (SD) P5 P25 P50 P75 P95
Myocardial infarction, n 13.5 (4.5) 7 10 13 16 21 9.7 (3.4) 4 7 9 12 15
Cerebrovascular
disease, n
11.5 (3.8) 6 9 11 14 18 8.9 (3.1) 4 7 9 11 14
COPD†, n 11.3 (5.8) 4 7 10 14 22 10.9 (5.7) 4 7 10 10 22
Asthma, n 3.3 (2.3) 0 1 3 5 7 0.8 (1.0) 0 0 1 1 3
Flu, n 366 (622) 7 27 106 343 1650 138 (248) 9 21 55 141 541
Acute respiratory
infections, n
5.2 (4.8) 0 2 4 7 16 8.3 (5.5) 2 5 7 11 18
Temperature, °C 20.4 (9) 7.8 12.4 18.3 28 34.2 19.8 (7.6) 8.4 13.4 19.5 26.1 32
PM10, 24 h µg m
3 36.9 (18.7) 13.6 22 34.1 47.3 72.1 40.5 (15.8) 19 29.6 38.5 49.2 68.5
SO2, 24 h µg m
3 12.6 (6.2) 6.8 8.3 10.2 15.1 26.2 3.8 (3.5) 1 1.1 2.4 5 10.9
NO2, 24 h µg m
3 60.7 (18.6) 34.1 47 58.5 71.9 96.1 73.4 (23.4) 39 55.4 71.9 89.1 114.5
O3, 8 h µg m
3 52.9 (27.1) 11.5 31.1 52.7 72.2 98.2 43.5 (26.3) 8 23 39 60 94
Poaceae, grains/m3 4.3 (16.4) 0 0 1 3 18 3 (7.5) 0 0 0.7 2.1 16.1
Plantago, grains/m3 0.8 (2.8) 0 0 0 0 4.9 0.9 (1.9) 0 0 0 0.7 4.9
Olea, grains/m3 2.9 (21.1) 0 0 0 0 10 3.3 (13.5) 0 0 0 0.7 19.5
Urticaceae, grains/m3 0.8 (2.1) 0 0 0 1 4 5.1 (7.9) 0 0.7 2.1 5.6 21.7
Madrid and Barcelona (Spain), 2003–2006 period.
*Percentile.
†Chronic obstructive pulmonary disease.
Galán I, et al. BMJ Open 2015;5:e008892. doi:10.1136/bmjopen-2015-008892 3
Open Access
−9.9%) and a reduction of 21.1% in Barcelona (95%
CI −26.3% to −15.5%). In both cities, admission rates for
COPD dropped substantially after adjusting for trend but
saw little variation when adjusted for the remaining
variables. In Barcelona, however, there was a moderate
reduction in admissions on adjustment for seasonality.
Modelling a quadratic trend (table 4, model F) explains
away the observed reductions in Madrid and yields a non-
significant 2.5% (95% CI −7.4% to 13.6%) increase in
admissions. In contrast, in Barcelona, a reduction of 16%,
though smaller than when correcting for linear trend,
remains statistically significant (95% CI −24.1 to −7.0%).
Regarding asthma, fully adjusted models point to non-
statistically significant changes in admission rates in both
cities but in opposite directions. Admissions in Madrid
experienced an increase of 10.5% (95% CI −2.9% to
25.7%), whereas in Barcelona hospital admissions
dropped by 15.4% (95% CI −34.0% to 8.4%). In Madrid,
accounting for pollen count substantially affects the esti-
mates, whereas in Barcelona, seasonality and tobacco
consumption turn out to be the confounders with the
most effect on the association between smoking ban and
hospital admissions for asthma.
Figure 1 Per day hospital admissions for cardiovascular and respiratory diseases in Madrid and Barcelona (Spain), 2003–2006
period (COPD, chronic obstructive pulmonary disease).
Table 3 Percentage rate change in hospital admissions
for myocardial infarction and cerebrovascular disease in
2006 versus the 2003–2005 period in Madrid and
Barcelona (Spain)
Percentage change (95% CI)
Madrid Barcelona
Myocardial infarction
Model A −1.9 (−6.7 to 3.1) −8.6 (−13.7 to −3.3)
Model B 4.5 (−3.1 to 12.7) −4.5 (−12.5 to 4.2)
Model C 5.2 (−2.3 to 13.4) −6.5 (−14.5 to 2.2)
Model D 6.3 (−1.4 to 14.5) −3.8 (−12.2 to 5.3)
Model E 6.6 (−1.5 to 15.5) −6.3 (−14.7 to 2.9)
Cerebrovascular disease
Model A 2.9 (−1.1 to 7.0) −2.2 (−6.2 to 2.0)
Model B −0.4 (−6.1 to 5.7) −9.1 (−14.6 to −3.2)
Model C −1.5 (−6.9 to 4.3) −9.1 (−14.8 to −3.0)
Model D −1.5 (−6.9 to 4.3) −9.6 (−15.3 to −3.5)
Model E 0.8 (−5.2 to 7.1) −10.2 (−16.1 to −3.8)
Model A, basic model, unadjusted; model B, adjusted for linear
secular trend; model C, additional adjustment for seasonality, day
of the week, temperature, flue and acute respiratory infections;
model D, additional adjustment for pollution levels; model E,
additional adjustment for tobacco consumption prevalence.
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DISCUSSION
Both cities experienced reductions in hospital admis-
sions for COPD during the first year of the smoking ban
implementation. Estimates remained statistically signifi-
cant even after adjusting for linear trend; however,
adjusting for quadratic trend renders the estimate for
Madrid non-significant. Similarly, admissions for cerebro-
vascular diseases in Barcelona decreased significantly.
No effects of the smoking ban on admissions for acute
myocardial infarction or asthma were detected. Our
sequential models suggest that results are sensitive to
trend adjustment and that the influence of other covari-
ates on the main association varies by disease and city of
interest.
The moderate effect of the smoking ban on the pre-
vention of hospital admissions for cardiovascular diseases
observed in our study is consistent with the literature sug-
gesting that benefits are observed mainly on regions with
comprehensive smoking laws banning smoking at the
workplace as well as in bars and restaurants.7 Regions
and countries where preventing SHS exposure is limited
to the workplace failed to observe any benefits14 30 or
were very limited.21 Two studies in Spain with a ‘pre-post’
design detected positive effects of the smoking ban on
hospital admissions for myocardial infarction. The first
one, performed in Barcelona between 2004 and 2006,23
detected an acceleration of the annual reduction close
to 5% in men and 2% in women, similar to our
trend-adjusted results (4.5%). The second study, carried
out in the province of Girona on the basis of data from
the REGICOR study,24 estimated a 11% decrease in hos-
pital admission risk for myocardial infarction in 2006–
2008 compared to 2002–2005.
Numerous previous studies have assessed the effect of
SHS exposure regulations on hospital admissions, but
few of them have controlled for potential confounding
variables. In time series studies, variables such as air pol-
lution, temperature or flu cases, which may vary along
the study period, are associated with both cardiovascular
and respiratory diseases.31 32 Only three studies included
temperature and flu cases17 33 34 and two also accounted
for atmospheric pollution (particles).17 34 In our results,
the effect of these variables is small, probably reflecting
the short study period, which limits data variability. An
exception is the COPD epidemic peak of 2005, which
may have been related to the large flu epidemic of the
same year.35 This variable is the main reason for the
moderate adjustment when controlling for seasonality in
the Barcelona model (model C), which slightly reduced
the size of the beneficial effect associated with the
smoking ban.
When it comes to evaluating the impact of regulations
on health outcomes, a key methodological issue regard-
ing model specification is the assumption of either a
linear or quadratic trend. Although some studies do not
adjust for underlying trend, most of them do adjust for a
linear one. However, two studies showed a change in esti-
mates when the trend was modelled as non-linear.
Gasparrini et al29 compared results from a statistical
model with a quadratic term versus one with a linear
term only to witness the previously observed protective
effect of the ban on hospital admissions for myocardial
infarction in a region of Italy disappear. Barr et al28 reran
analyses on data from 387 US counties and also observed
how the effects of the smoking ban on hospital admis-
sions for myocardial infarction were dampened until the
risk estimate equalled 0 after modelling non-linear terms
based on cubic splines with different degrees of
freedom. Non-linear adjustment may be of particular
importance when the number of years in the series is
large, as the probability of detecting non-linear trends
increases with the number of years under study. In our
work, we only observed a quadratic trend in the years
before the smoking ban for COPD, and this is very likely
due to the COPD increase due to the 2005 flu. As in
previous studies, modelling a quadratic trend rendered
the possible ban effect in Madrid null and reduced the
magnitude of the effect in Barcelona. Nonetheless, mod-
elling non-linear terms remains controversial due to the
high probability of capturing the very own regulation
effect, to the point of making it disappear.
Tobacco consumption is another important variable to
examine in this context because it is related to both the
regulation as well as to its effect. On the one hand, it is
Table 4 Percentage rate change in hospital admissions for
chronic obstructive pulmonary disease and asthma in 2006
versus the 2003–2005 period in Madrid and Barcelona
(Spain)
Percentage change (95% CI)
Madrid Barcelona
COPD
Model A −20.4 (−25.1 to −15.5) −36.3 (−40.2 to −32.2)
Model B −14.5 (−21.7 to −6.6) −24.6 (−30.9 to −17.7)
Model C −15.6 (−21.0 to −9.9) −21.1 (−26.1 to −15.7)
Model D −15.8 (−21.2 to −10.1) −20.7 (−25.8 to −15.3)
Model E −16.0 (−21.6 to −9.9) −21.1 (−26.3 to −15.5)
Model F 2.5 (−7.4 to 13.6) −16.0 (−24.1 to −7.0)
Asthma
Model A 26.5 (16.4 to 37.4) −24.7 (−35.8 to −11.7)
Model B 20.0 (5.3 to 36.7) −19.8 (−36.2 to 0.8)
Model C 24.2 (9.9 to 40.2) −9.2 (−28.4 to 15.2)
Model D 27.0 (12.4 to 43.5) −9.8 (−29.0 to 14.6)
Model E 11.2 (−1.5 to 25.5) −10.2 (−29.3 to 14.0)
Model F 10.5 (−2.9 to 25.7) −15.4 (−34.0 to 8.4)
COPD (chronic obstructive pulmonary disease): model A, basic
model, unadjusted; model B, adjusted for linear secular trend;
model C, additional adjustment for seasonality, day of the week,
temperature, flue and acute respiratory infections; model D,
additional adjustment for pollution levels; model E, additional
adjustment for tobacco consumption prevalence; model F, full
model adjusted for quadratic secular trend.
Asthma: model A, basic model, unadjusted; model B, adjusted for
linear secular trend; model C, additional adjustment for
seasonality, day of the week, temperature, flue and acute
respiratory infections; model D, additional adjustment for pollution
levels; model E, additional adjustment for pollen count; model F,
additional adjustment for tobacco consumption prevalence.
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a greater risk factor than SHS exposure. On the other
hand, its prevalence and intensity are positively corre-
lated with SHS exposure. In addition, a smoking ban
may have a beneficial effect on tobacco consumption
prevalence and the number of cigarettes smoked as
observed in Italy,36 and with the increase in ex-smokers
in England.37 In Spain, smoking prevalence, slightly
decreasing both in men and women, has not been
affected by the ban, similar to what has been observed
in countries around us.8 38 The ban’s effect on estimates,
except for the change in hospitalisations for asthma in
Barcelona, is moderate overall. This could be due in
part to the trend variable itself, which captures time-
related variations in risk factors or protective factors,
masking part of the ban’s effect on hospital admissions.
Another consideration is the variability between
regions of similar geographic characteristics where the
regulation is implemented. We observed variability in
the results reported from the two cities under study;
further, in some estimates, variability is greater than the
one expected due to chance. Sources of this heterogen-
eity are not clear but they may be related to the actual
implementation. Madrid is the region with the highest
number of police report filings for smoking ban viola-
tions (weighed by population size), whereas Catalonia,
the region encompassing the city of Barcelona, is among
the regions with the lowest filings. There were four more
reports filed in Madrid than in Catalonia and four times
as many fines imposed per number of inspected
venues.39 This variability between regions has been high-
lighted by Shetty et al30 who showed that positive and
negative changes in acute myocardial infarction inci-
dence were equally likely after a smoking ban in the
USA and comparisons of small samples might have led
to atypical findings.
SHS prevention has unambiguously beneficial effects
on several health outcomes. However, policy evaluation
reveals that a statewide ban on smoking in public places
would have drawn atypical conclusions depending on
the condition selected. These results reinforce the need
to test multiple outcomes, and the evaluation should
consider systematic approaches to account for the issues,
including alternative model specifications and sensitivity
analyses.40 In our study, several sensitivity analyses have
been run testing different ways to control for the poten-
tial confounders. For instance, we examined three flu
indicators and tobacco consumption was also assessed
using cigarette sales. We also reanalysed the data using
only incident cases, eliminating hospital readmissions
for the same disease based on the identification of the
case by sex, birth date and province of residence. Results
did not vary significantly. Additional variables potentially
related to hospital admissions for cardiovascular dis-
eases, such as consumption of statins, antidiabetic drugs
and antihypertensive drugs, were not included in the
analyses given that their lineal or exponential consump-
tion pattern growth destabilised our parameters for
trend or tobacco consumption.41 Their effect, however,
is very likely captured indirectly in the term for trend in
the time series.
Our results should be interpreted taking into account
the following limitations. First, causality cannot be
inferred given the ecological nature of the study.
Second, the characteristics of hospital admissions regis-
try did not allow the collection of individual information
such as tobacco consumption. Third, despite adjusting
for important covariates, changes in other factors not
controlled for here may have influenced our results.
Similarly, although our time series include only a few
years, we cannot ignore the possibility of administrative
changes related to the registry associated with the hospi-
talisation of the diseases of interest. Finally, since the
smoking ban was implemented in all regions of Spain
simultaneously, there is no control population to
compare our results against.
Among the strengths of the study, the two main ones
are that the data came from large samples of two large
metropolitan cities and that we were able to include
many covariates with objective measures taken at the
local level, not examined in the most previous studies.
To conclude, the potential impact of the smoking ban
must be adjusted for the underlying secular trend, in
addition to pollen count, seasonality and tobacco con-
sumption in the case of hospital admissions for asthma.
The variability in estimates observed across the two cities
in the same country strongly suggests the need to study a
larger number of regions to globally assess the impact of
smoking. The Spanish partial smoking ban was effective
in reducing SHS exposure at the workplace, while
having no impact on active tobacco consumption, and
so far the results on cardiovascular and respiratory mor-
bidity have proven inconsistent. A future evaluation of
the second ban implemented in January 2011, prohibit-
ing smoking in all public places, will help us elucidate
the global impact of a comprehensive smoke-free policy
on health outcomes.
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